{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T06:30:54Z","timestamp":1781850654379,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T00:00:00Z","timestamp":1551916800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12882-019-1273-6","type":"journal-article","created":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T13:04:35Z","timestamp":1551963875000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Dasatinib-induced nephrotic syndrome in a patient with chronic myelogenous leukemia: a case report"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7699-0560","authenticated-orcid":false,"given":"Shoko","family":"Ochiai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Minakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouichi","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,7]]},"reference":[{"key":"1273_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3322\/caac.21395","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177\u201393.","journal-title":"CA Cancer J Clin"},{"key":"1273_CR2","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1056\/NEJM200104053441409","volume":"344","author":"JM Goldman","year":"2001","unstructured":"Goldman JM, Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1084\u20136.","journal-title":"N Engl J Med"},{"key":"1273_CR3","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","volume":"66","author":"JS Tokarski","year":"2006","unstructured":"Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE, et al. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against Imatinib-resistant ABL mutants. Cancer Res. 2006;66:5790\u20137.","journal-title":"Cancer Res"},{"key":"1273_CR4","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1053\/j.ajkd.2013.01.022","volume":"61","author":"E Wallace","year":"2013","unstructured":"Wallace E, Lyndon W, Chumley P, Jaimes EA, Fatima H. Dasatinib-induced nephrotic-range proteinuria. Am J Kidney Dis. 2013;61:1026\u201331.","journal-title":"Am J Kidney Dis"},{"key":"1273_CR5","doi-asserted-by":"publisher","first-page":"726","DOI":"10.3109\/10428194.2015.1075020","volume":"57","author":"T Hirano","year":"2016","unstructured":"Hirano T, Hashimoto M, Korogi Y, Tsuji T, Miyanaka K, Yamasaki H, et al. Dasatinib-induced nephrotic syndrome. Leuk Lymphoma. 2016;57:726\u20137.","journal-title":"Leuk Lymphoma"},{"key":"1273_CR6","doi-asserted-by":"crossref","unstructured":"Ruebner RL, Copelovitch L, Evageliou NF, Denburg MR, Belasco JB, Kaplan BS. Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature. Pediatr Nephrol 2014;29:863\u2013869.","DOI":"10.1007\/s00467-013-2696-0"},{"key":"1273_CR7","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3349\/ymj.2016.57.2.532","volume":"57","author":"YT Lim","year":"2016","unstructured":"Lim YT, Kim YJ, Park YH, Hah JO, Lee JM. A case of dasatinib-induced nephrotic syndrome in a child with Philadelphia chromosome positive acute lymphoblastic leukemia. Yonsei Med J. 2016;57:532\u20133.","journal-title":"Yonsei Med J"},{"key":"1273_CR8","first-page":"1106","volume":"3","author":"ML Luca De","year":"2016","unstructured":"De Luca ML, Carmosino I, Stefanizzi C, Campanelli M, De Angelis F, Cesini L, et al. Nephrotic proteinuria developed under dasatinib treatment in a patient with chronic myeloid leukemia: a case report and review of the literature. Ann Hematol Oncol. 2016;3:1106.","journal-title":"Ann Hematol Oncol"},{"key":"1273_CR9","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s10157-011-0543-9","volume":"16","author":"D Takahashi","year":"2012","unstructured":"Takahashi D, Nagahama K, Tsuura Y, Tanaka H, Tamura T. Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction. Clin Exp Nephrol. 2012;16:310\u20135.","journal-title":"Clin Exp Nephrol"},{"key":"1273_CR10","first-page":"2014","volume":"28","author":"KI Quintyne","year":"2014","unstructured":"Quintyne KI, Neenan T, Casserly L, Gupta R. Uncommon side effect with a commonly used targeted agent: sunitinib-induced nephrotic syndrome in a patient with metastatic renal cell carcinoma. BMJ Case Rep. 2014;28:2014.","journal-title":"BMJ Case Rep"},{"key":"1273_CR11","doi-asserted-by":"publisher","first-page":"6232","DOI":"10.1158\/1078-0432.CCR-09-0224","volume":"15","author":"GD Demetri","year":"2009","unstructured":"Demetri GD, Lo Russo P, MacPherson IR, Wang D, Morgan JA, Brunton VG, et al. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res. 2009;15:6232\u201340.","journal-title":"Clin Cancer Res"},{"key":"1273_CR12","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1158\/1078-0432.CCR-10-2616","volume":"17","author":"JC Montero","year":"2011","unstructured":"Montero JC, Seoane S, Oca\u00f1a A, Pandiella A. Inhibition of Src family kinases and receptor tyrosine kinases by Dasatinib: possible combinations in solid tumors. Clin Cancer Res. 2011;17:5546\u201352.","journal-title":"Clin Cancer Res"},{"key":"1273_CR13","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1158\/1078-0432.CCR-09-1486","volume":"16","author":"W Liang","year":"2010","unstructured":"Liang W, Kujawski M, Wu J, Lu J, Herrmann A, Loera S, et al. Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment. Clin Cancer Res. 2010;16:924\u201335.","journal-title":"Clin Cancer Res"},{"key":"1273_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/01.mnh.0000437329.41546.a9","volume":"23","author":"A Advani","year":"2014","unstructured":"Advani A. Vascular endothelial growth factor and the kidney: something of the marvellous. Curr Opin Nephrol Hypertens. 2014;23:87\u201392.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"1273_CR15","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/his.13716","volume":"73","author":"F Pfister","year":"2018","unstructured":"Pfister F, Amann K, Daniel C, Klewer M, B\u00fcttner A, B\u00fcttner-Herold M. Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy. Histopathology. 2018;73:990\u20131001.","journal-title":"Histopathology."},{"key":"1273_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7:129\u201341.","journal-title":"Cancer Cell"},{"key":"1273_CR17","doi-asserted-by":"publisher","first-page":"R114","DOI":"10.1186\/cc12786","volume":"20","author":"IK Kim","year":"2013","unstructured":"Kim IK, Rhee CK, Yeo CD, Kang HH, Lee DG, Lee SH, et al. Effect of tyrosine kinase inhibitors, imatinib and nilotinib, in murine lipopolysaccharide-induced acute lung injury during neutropenia recovery. Crit Care. 2013;20:R114.","journal-title":"Crit Care"},{"key":"1273_CR18","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/sj.ki.5002222","volume":"71","author":"RC Wiggins","year":"2007","unstructured":"Wiggins RC. The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int. 2007;71:1205\u201314.","journal-title":"Kidney Int"},{"key":"1273_CR19","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1681\/ASN.2007121328","volume":"20","author":"Y Sato","year":"2009","unstructured":"Sato Y, Wharram BL, Lee SK, Wickman L, Goyal M, Venkatareddy M, et al. Urine podocyte mRNAs mark progression of renal disease. J Am Soc Nephrol. 2009;20:1041\u201352.","journal-title":"J Am Soc Nephrol"},{"key":"1273_CR20","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1046\/j.1523-1755.2003.00853.x","volume":"63","author":"JL Rosenstock","year":"2003","unstructured":"Rosenstock JL, Markowitz GS, Valeri AM, Sacchi G, Appel GB, D'Agati VD. Fibrillary and immunotactoid glomerulonephritis: distinct entities with different clinical and pathologic features. Kidney Int. 2003;63:1450\u201361.","journal-title":"Kidney Int"},{"key":"1273_CR21","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0272-6386(12)70138-5","volume":"22","author":"A Fogo","year":"1993","unstructured":"Fogo A, Qureshi N, Horn RG. Morphologic and clinical features of fibrillary glomerulonephritis versus immunotactoid glomerulopathy. Am J Kidney Dis. 1993;22:367\u201377.","journal-title":"Am J Kidney Dis"},{"key":"1273_CR22","doi-asserted-by":"publisher","first-page":"775","DOI":"10.2215\/CJN.08300910","volume":"6","author":"SH Nasr","year":"2011","unstructured":"Nasr SH, Valeri AM, Cornell LD, Fidler ME, Sethi S, Leung N, et al. Fibrillary glomerulonephritis: a report of 66 cases from a single institution. Clin J Am Soc Nephrol. 2011;6:775\u201384.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1273_CR23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ekir.2017.07.017","volume":"3","author":"SH Nasr","year":"2018","unstructured":"Nasr SH, Vrana JA, Dasari S, Bridoux F, Fidler ME, Kaaki S, et al. DNAJB9 is a specific Immunohistochemical marker for fibrillary glomerulonephritis. Kidney Int Rep. 2018;3:56\u201364.","journal-title":"Kidney Int Rep"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1273-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-019-1273-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1273-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:13:21Z","timestamp":1583453601000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1273-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,7]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1273"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1273-6","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,7]]},"assertion":[{"value":"13 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report. A copy of the written consent form is available for review by the editor of the journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"87"}}